Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

Apricus Biosciences (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter of 2017 and provided a corporate update on its near-term priorities.

As quoted in the press release:

“Since the end of the third quarter of 2017, we have been focused on supporting the Vitaros NDA resubmission and strengthening our balance sheet.  While we were successful achieving the latter, we were extremely disappointed with the FDA’s recent decision regarding the approval of Vitaros.  As such, we will submit a request to the FDA for an end-of-review meeting in the coming weeks with a meeting expected to be scheduled in April per FDA guidelines.  Our objective for this meeting is to determine the specific requirements needed to address the deficiencies noted in the Complete Response,” stated Richard W. Pascoe, Chief Executive Officer.  “In parallel, we will focus our efforts on identifying and evaluating opportunities or business combinations to maximize shareholder value, as we look reduce our expenses and extend our cash runway.”

Click here to read the full press release.